A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Recruiting · NCT07123415 · Registry updated 2026-10-09Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | Advanced Solid Cancer; Advanced Solid Tumor (Phase 1) | Recruiting | Phase 1 | 2026-10-09 | NCT07123415 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Aptabio Therapeutics, Inc. | 3 |
| Merck Sharp & Dohme LLC | 650 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Gangnam Severance Hospital, Yonsei University Health System | Seoul | South Korea | 5 |
| Seoul National University Bundang Hospital | Seongnam | South Korea | 42 |
| Severance Hospital, Yonsei University Health System | Seoul | South Korea | 43 |